MAO inhibitors and psilocybin.
12 records in this group. 3 have published human data with psilocybin or another classic psychedelic; the rest draw on each medication's own pharmacology and label. State rules are summarized for Colorado, Oregon and New Mexico.
Overview
Reviewed 2026-10-25The most serious reported event with this class is a hypertensive emergency (dangerously high blood pressure). In one case report, a person taking tranylcypromine with extended-release dextroamphetamine-amphetamine took psilocybin mushrooms, developed chest pain, palpitations and headache, and was diagnosed with a heart attack; emergency catheterization found no significant cardiac abnormalities. The authors attributed the event to phenylethylamine in the mushrooms (Barnett 2024). Amphetamine labeling contraindicates use with, or within 14 days of, an MAO inhibitor (dextroamphetamine-amphetamine prescribing information). In a small placebo-controlled study of 9 patients abstinent from alcohol, 2 days of tranylcypromine increased psilocybin's blood pressure and pupil effects (Vojtěchovský 1968, as summarized in Tap 2025).
Phenelzine's label describes hypertensive crises with certain drugs and with foods high in tyramine, contraindicates use with serotonergic drugs, and describes at least 14 days between stopping phenelzine and starting another antidepressant; the label does not address psilocybin (Nardil prescribing information). Neither of the two human reports of psilocybin with an MAO inhibitor described serotonin toxicity (Vojtěchovský 1968; Barnett 2024, as summarized in Tap 2025); the published data are small.
In the same 9-person study, tranylcypromine did not significantly reduce psilocybin's subjective effects (Vojtěchovský 1968). With LSD, long-term phenelzine nearly abolished the response in 2 people (Bonson & Murphy 1996), and 2 to 5 weeks of isocarboxazid reduced it in 4 healthy volunteers (Resnick 1964, as summarized in Tap 2025). The patient in the case report above had earlier had no noticeable effects from psilocybin mushrooms while taking phenelzine and nortriptyline (Barnett 2024).
Monoamine oxidase also helps clear psilocin, psilocybin's active form. In lab studies, one group found MAO-A formed only small amounts of 4-HIAA from psilocin, while another estimated MAO-A at about 81% of psilocin's Phase I liver clearance (Thomann 2024; Chen 2025). Psilocin is also cleared by glucuronidation (Thomann 2024). Whether MAO inhibitors raise psilocin levels in people has not been measured.
This class also includes drugs with MAO-inhibiting effects used for other purposes, such as linezolid, methylene blue, selegiline, rasagiline, safinamide, procarbazine and isoniazid, and the harmala alkaloids in Syrian rue and ayahuasca. How strongly each inhibits MAO-A differs; each record gives the details.
Psilodex presents published evidence and state psilocybin regulations for information only. It is not medical advice, a screening decision, or clearance to participate. Do not stop or change a medication without talking with the prescriber.
- Barnett BS, Koons CJ, Van den Eynde V, et al. Hypertensive emergency secondary to combining psilocybin mushrooms, extended release dextroamphetamine-amphetamine, and tranylcypromine. J Psychoactive Drugs 2024;57(3):297–303.
- Vojtěchovský M, Hort V, Šafratová V. Influence of MAO inhibitors on psilocybine induced psychosis. Activitas Nervosa Superior 1968;10(3):278–279 (via Tap 2025).
- Tap SC, Thomas K, Páleníček T, et al. Concomitant use of antidepressants and classic psychedelics: a scoping review. J Psychopharmacol 2025.
- Bonson KR, Murphy DL. Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium. Behav Brain Res 1996;73:229–233.
- Resnick O, Krus DM, Raskin M. LSD-25 action in normal subjects treated with a monoamine oxidase inhibitor. Life Sci 1964;3:1207–1214.
- Thomann J, Kolaczynska KE, Stoeckmann OV, et al. In vitro and in vivo metabolism of psilocybin’s active metabolite psilocin. Front Pharmacol 2024;15:1391689.
- Chen J, Wang Z, Yong CY, et al. Elucidating the Phase I metabolism of psilocin in vitro. Arch Toxicol 2025;99(3):1085–1094.
- Dextroamphetamine–amphetamine extended-release prescribing information (DailyMed)
- Nardil (phenelzine) prescribing information (DailyMed)
Also searched as MAO inhibitor · MAOI · MAOIs · RIMA · ayahuasca · harmala
01 What the evidence covers
Best evidence available per medication| 1 | Controlled trial |
| 1 | Case reports Case reports or online surveys |
| 1 | Other psychedelic Human data with another classic psychedelic (e.g. LSD), not psilocybin; named in the text |
| 9 | No psilocybin data No psilocybin data: no human data with psilocybin or another classic psychedelic; the text draws on the medication's own pharmacology and its label or reference facts |
02 Each medication
A to ZDepression
It reduced LSD's effects in a small study; it is unstudied with psilocybin, and blood pressure changes with the combination are possible.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- IsoniazidEvidence: No psilocybin data
Tuberculosis (all forms, with other antituberculosis drugs); Preventive therapy for tuberculosis infection in higher-risk groups
Its label reports some MAO (an enzyme) inhibiting activity, so it may alter how the body clears psilocybin. Also, it can cause severe hepatitis.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Pneumonia (hospital- and community-acquired); Skin and skin structure infections (including diabetic foot infections)
It weakly blocks MAO (an enzyme), so it may alter how the body clears psilocybin; its label warns of serotonin syndrome with serotonin-boosting drugs.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Acquired methemoglobinemia (blood unable to carry oxygen normally)
In people, related drugs weakened psychedelic effects and raised psilocybin's blood pressure effect, so it is expected to do the same.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Psychotropics
In people, related drugs weakened psychedelic effects and raised psilocybin's blood pressure effect, so it is expected to do the same.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression (particularly atypical depression)
Its label contraindicates use with serotonergic drugs, a class that includes psilocybin; in one case, psilocybin mushrooms had no noticeable effect.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Stage III and IV Hodgkin's disease (with other anticancer drugs, MOPP regimen)
Not studied with psilocybin; related enzyme-blocking (MAO) drugs weakened psychedelic effects and raised psilocybin's blood pressure effects.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Parkinson's disease
Not studied with psilocybin; it mainly blocks one enzyme (MAO-B) at usual doses. Also, its label warns of serotonin syndrome with antidepressants.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Parkinson's disease "off" episodes (add-on to levodopa/carbidopa)
Not studied with psilocybin; it mainly blocks one enzyme (MAO-B). Its label warns of high blood pressure and serotonin syndrome with serotonin-boosting drugs.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Parkinson's disease (add-on to levodopa/carbidopa); Major depressive disorder in adults (Emsam patch)
Not studied with psilocybin; usual oral doses mainly block one enzyme (MAO-B), but the patch or higher doses may raise psilocybin levels and blood pressure.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
- Syrian rue / harmala / ayahuascaEvidence: No psilocybin data
Other substances
Based on related antidepressants, it is expected to weaken psilocybin's felt effects and raise blood pressure. Ayahuasca also contains DMT, another psychedelic.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
Depression in adults not responding to other antidepressants
Its label contraindicates use with serotonergic drugs, a class that includes psilocybin; in one small 1968 study, it increased psilocybin's blood pressure rise.
CO: not mentioned in rule · OR: not mentioned in rule · NM: rules not final
03 Properties the records flag
Records with each flag| 12 | MAO inhibition |
| 10 | Raises blood pressure or heart rate |
| 10 | Serotonergic |
| 6 | Psychiatric reactions |
| 5 | Lowers blood pressure or causes orthostasis |
| 5 | Withdrawal or rebound if stopped abruptly |
| 3 | Sedating or CNS depressant |
| 2 | Hypoglycemia risk |
| 2 | Lowers seizure threshold or carries seizure risk |
| 1 | Liver injury |
Flags describe a medication's own properties, each cited in its record. A flag is not a finding about any combination. Definitions are on the Method page.
04 State rules
Official text governsNo provision names these medications or this group.
Rule 2.2(A)(9): a facilitator must tell prospective participants in writing that anyone taking a psychotropic medication identified as a risk factor on the safety screen must meet one of the 2.2(A)(7) conditions. 5 of the 12 medications in this group are psychotropic; the rule applies when one is identified as a risk factor on a participant's screen.
No provision names these medications or this group.
Rules not final; the proposed rules reviewed name no medication in this group.
05 Studies cited in this group
Records citing eachRelated classes
- Antidepressants5 shared
- Parkinson's medications3 shared
- Antibiotics2 shared
Records reviewed 2026-10-14. Each row summarizes one record; the full record, with every source, opens in the browser and is not sent to the server. All classes · Browse A–Z